

MITRE / FLUX NOTES **TREATMENT OPTIONS v4**

EDWIN CHOI, DANIEL REEVES, JUHAN SONIN, 29.NOV.2018




Treatment Options Visualization

The patient has a history of unsuccessful treatments, or some other complicating factor. The provider compares across treatment regiments to see which have most successful outcomes for patients like this one.

outcomes from many patients with various treatments

apply filter for similar patients
genetics
stage
race
cancer type
etc.

compare treatments
survival rates
quality of life scores
side effects
etc.





encounters for you with this patient. No recent visits to this facility are on record. As of 18 Oct 2017, disease is stable, neither improving nor worsening based on [missing](#). No recent [lab results](#). Key toxicities include [Grade 3 peripheral motor neuropathy](#) (as of 18 Oct 2017), no blood clots, no neutropenia, no nausea/vomiting. Patient is [ER Negative](#), [PR Positive](#), and [HER2 Positive](#).

Summary

Treatment Options

Treatment Options Ductal carcinoma of the breast

Outcomes and criteria for 156,765 patients with Ductal carcinoma of the breast were collected by CancerLinQ [...more](#)

> Similar patients 156 patients

excluded criteria: race, sex, family history, surgery

> Filter treatments all treatment types

most common 3 treatments + "none"

> Features cancer specific survival rate, ECOG score, Hospitalization due to side effects

[%](#) <#>

select to compare		Cancer specific survival rates			ECOG score (0 – 4)	Hospitalization due to side effects	
		1 yr	2 yr	5 yr		all	leading causes
surgery & radiation	(64)	87% <div><div></div></div>	74% <div><div></div></div>	58% <div><div></div></div>	2.3	32%	peripheral motor... (15%) blood clots (10%)
hormonal therapy	(84)	77% <div><div></div></div>	59% <div><div></div></div>	49% <div><div></div></div>	2.2	32%	peripheral motor... (15%) blood clots (10%)
chemotherapy	(12)	68% <div><div></div></div>	53% <div><div></div></div>	41% <div><div></div></div>	2.4	32%	peripheral motor... (15%) blood clots (10%)
none (actively monitoring)	(3)	67% <div><div></div></div>	54% <div><div></div></div>	43% <div><div></div></div>	2	32%	peripheral motor... (15%) blood clots (10%)



encounters for you with this patient. No recent visits to this facility are on record. As of 18 Oct 2018, disease is Stable, neither improving nor worsening based on missing. No recent lab results. Key toxicities include Grade 3 peripheral motor neuropathy (as of 18 Oct 2017), no blood clots, no neutropenia, no nausea/vomiting. Patient is ER Negative, PR Positive, and HER2 Positive.

Summary

Treatment Options Ductal carcinoma of the breast

Outcomes and criteria for 156,765 patients with Ductal carcinoma of the breast were collected by CancerLinQ [...more](#)

- > **Similar patients** 156 patients
excluded criteria: race, sex, family history, surgery
- > **Filter treatments** all treatment types
most common 3 treatments + "none"
- > **Features** cancer specific survival rate, ECOG score, Hospitalization due to side effects

% #

Treatment Options

select to compare		Cancer specific survival rates			ECOG score (0 – 4)	Hospitalization due to side effects	
		1 yr	2 yr	5 yr		all	leading causes
surgery & radiation	(64)	87% ▲20%	74% ▲20%	58% ▲15%	2.3 ▲0.3	15% ▼4%	peripheral motor... (15%) blood clots (10%)
hormonal therapy	(84)	77% ▲10%	59% ▲5%	49% ▲6%	2.2 ▲0.2	23% ▲4%	peripheral motor... (15%) blood clots (10%)
chemotherapy	(12)	68% ▲1%	53% ▼1%	41% ▼2%	2.4 ▲0.4	22% ▲3%	peripheral motor... (15%) blood clots (10%)
none (actively monitoring)	(3)	67%	54%	43%	2	19%	peripheral motor... (15%) blood clots (10%)



Treatment Options Ductal carcinoma of the breast

Outcomes and criteria for 156,765 patients with Ductal carcinoma of the breast were collected by CancerLinQ [...more](#)

> Similar patients 156 patients

excluded criteria: race, received radiation therapy, received chemotherapy

[select all](#) [select none](#)

▼ ☐ demographic 3/4

- ☒ age: 41-61
- ☒ age at diagnosis: 41-61
- ☐ race: white
- ☒ sex: female

▼ ☒ genetics 2/2

- ☒ BRCA1: negative
- ☒ BRCA2: negative

▼ ☒ pathology 5/5

- ☒ ER: negative
- ☒ PR: positive
- ☒ HER2: positive
- ☒ grade: 3
- ☒ size (mm): 10-20

▼ ☐ treatment history 1/3

- ☒ had surgery: yes
- ☐ received radiation therapy: yes
- ☐ received chemotherapy: yes

> Filter treatments all treatment types

Compare across:

- ☒ All treatment types
- ☐ Chemotherapy regimens
- ☐ Hormonal therapy regimens

Surgery:

- ☐ must include
- ☐ must NOT include
- ☒ all

Radiation:

- ☐ must include
- ☐ must NOT include
- ☒ all

Most common

- ☐ 3
- ☐ 5
- ☐ 10
- ☒ all

☐ at least patients

☒ Include "none"

> Outcomes overall survival rate, ECOG score, Hospitalization due to side effects

% #

select to compare		overall survival rates			ECOG score (0 – 4)	Hospitalization due to side effects	
		1 yr	2 yr	5 yr		all	leading causes
surgery & radiation	(64)	87% <div><div></div></div>	74% <div><div></div></div>	58% <div><div></div></div>	2.3	32%	peripheral motor... (15%) blood clots (10%)
hormonal therapy	(84)	77% <div><div></div></div>	59% <div><div></div></div>	49% <div><div></div></div>	2.2	32%	peripheral motor... (15%) blood clots (10%)